• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Conformis Inc. (Amendment)

    2/14/23 12:20:12 PM ET
    $CFMS
    Industrial Specialties
    Health Care
    Get the next $CFMS alert in real time by email
    SC 13G/A 1 armistice-cfms123122a3.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*



    Conformis, Inc.

    (Name of Issuer)

     

    Common Stock, $0.00001 par value

    (Title of Class of Securities)

     

    20717E200

    (CUSIP Number)

     

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  20717E200
     SCHEDULE 13G/A
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    480,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    480,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    480,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    6.00%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  20717E200
     SCHEDULE 13G/A
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    480,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    480,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    480,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    6.00%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 20717E200
     SCHEDULE 13G/A
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    Conformis, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    600 Technology Park Drive

    Billerica, MA 01821

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common Stock, $0.00001 par value (“Shares”)

     

    Item 2.(e) CUSIP No.:

    20717E200

     

    CUSIP No.  20717E200
     SCHEDULE 13G/A
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 20717E200
     SCHEDULE 13G/A
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of December 31, 2022:

    Armistice Capital, LLC - 480,000

    Steven Boyd - 480,000 

    (b) Percent of Class as of December 31, 2022:

    Armistice Capital, LLC - 6.00%

    Steven Boyd - 6.00% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 480,000

    Steven Boyd - 480,000 

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 480,000

    Steven Boyd - 480,000

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on 7,996,756 Shares outstanding as of November 9, 2022, as reported on the Issuer’s Form 8-K filed with the Securities and Exchange Commission on November 9, 2022.

    Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 20717E200
     SCHEDULE 13G/A
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 20717E200
     SCHEDULE 13G/A
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2023

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $CFMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CFMS

    DatePrice TargetRatingAnalyst
    11/4/2021$2.50 → $2.00Outperform
    Oppenheimer
    9/22/2021$3.00 → $2.50Outperform
    Oppenheimer
    More analyst ratings

    $CFMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Fischetti Gary P returned 10,470 shares to the company, closing all direct ownership in the company

      4 - Conformis Inc (0001305773) (Issuer)

      9/5/23 6:13:51 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form 4: Johnston Philip W returned 19,273 shares to the company, closing all direct ownership in the company

      4 - Conformis Inc (0001305773) (Issuer)

      9/5/23 6:13:47 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form 4: Augusti Mark A was granted 17,778 shares and returned 190,277 shares to the company, closing all direct ownership in the company

      4 - Conformis Inc (0001305773) (Issuer)

      9/5/23 6:13:53 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Conformis Inc.

      15-12G - Conformis Inc (0001305773) (Filer)

      9/15/23 9:56:53 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form S-8 POS filed by Conformis Inc.

      S-8 POS - Conformis Inc (0001305773) (Filer)

      9/5/23 6:08:15 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form S-8 POS filed by Conformis Inc.

      S-8 POS - Conformis Inc (0001305773) (Filer)

      9/5/23 6:08:13 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Financials

    Live finance-specific insights

    See more
    • Conformis Reports First Quarter 2023 Financial Results

      BILLERICA, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2023. First Quarter 2023 Summary Total revenue of $12.8 million, a decrease of 17% year-over-year on a reported and constant currency basis.Product revenue of $12.7 million, a decrease of 15% year-over-year on a reported basis and 14% on a constant currency basis.Conformis hip system revenue of $0.8 million, an increase of 3% year-over-year.Cash and cash equivalents of $37.8 million as of March 31, 2023.   Three months ended March 31,

      5/8/23 8:05:00 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. to Announce Financial Results for Its First Quarter on May 8, 2023

      BILLERICA, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the first quarter ended March 31, 2023, before the market opens on Monday, May 8, 2023. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the financial results and provide a business update. Earnings Call and Webcast Details: The webcast of the earnings call will be live at: Link Directly to Webcast To attend by telephone, please use the information below for dial-in access. Date and Time

      4/13/23 4:30:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. Reports Fourth Quarter and Year End 2022 Financial Results

      BILLERICA, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter 2022 Summary Total revenue of $17.4 million, an increase of 13% year-over-year on a reported basis and 14% on a constant currency basis.Product revenue of $14.2 million, a decrease of 7% year-over-year on a reported basis and 6% on a constant currency basis.Hip system revenue of $0.6 million, a decrease of 15% year-over-year.Cash and cash equivalents of $48.7 million as of December 31, 2022.First procedur

      3/1/23 4:05:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Conformis Inc. (Amendment)

      SC 13G/A - Conformis Inc (0001305773) (Subject)

      7/10/23 5:14:02 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Conformis Inc. (Amendment)

      SC 13G/A - Conformis Inc (0001305773) (Subject)

      2/14/23 12:20:12 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Conformis Inc. (Amendment)

      SC 13G/A - Conformis Inc (0001305773) (Subject)

      2/13/23 10:56:02 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • restor3d Completes Acquisition of Conformis

      DURHAM, North Carolina and BILLERICA, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. announced today that restor3d has completed its previously announced acquisition of Conformis following the approval of Conformis' stockholders at a special meeting held on August 31, 2023. In connection with the completion of the acquisition, shares of Conformis' common stock ceased trading on the NASDAQ prior to the opening of the NASDAQ on September 5, 2023. "We are extremely excited to complete this important transaction and look forward to leveraging our combined portfolio to deliver personalized orthopedic solutions for the whole human body," said J. Kurt Jacobus, CEO o

      9/5/23 8:18:31 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Conformis Stockholders Vote "FOR" the Pending Merger with restor3d

      BILLERICA, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co., LLC ("Glass Lewis"), have each recommended that Conformis stockholders vote "FOR" the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstanding shares of common stock of Conformis for $2.27 per share in an all cash transaction. Conformis is pleased that ISS and Glass Lewis share its be

      8/23/23 8:00:00 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote "FOR" the Pending Merger with restor3d

      BILLERICA, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. ("ISS"), has recommended that Conformis stockholders vote "FOR" the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstanding shares of common stock of Conformis for $2.27 per share in an all cash transaction. Conformis is pleased that ISS shares its belief that the proposed merger with restor3d is in the best inte

      8/21/23 4:10:25 PM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer reiterated coverage on Conformis with a new price target

      Oppenheimer reiterated coverage of Conformis with a rating of Outperform and set a new price target of $2.00 from $2.50 previously

      11/4/21 10:00:09 AM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Oppenheimer reiterated coverage on Conformis with a new price target

      Oppenheimer reiterated coverage of Conformis with a rating of Outperform and set a new price target of $2.50 from $3.00 previously

      9/22/21 7:20:22 AM ET
      $CFMS
      Industrial Specialties
      Health Care

    $CFMS
    Leadership Updates

    Live Leadership Updates

    See more
    • Conformis, Inc. Appoints Michael Fillion as Chief Operating Officer

      BILLERICA, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced today that Michael Fillion has joined the Company as its Chief Operating Officer. "We are pleased to announce the addition of Michael Fillion as Chief Operating Officer. Mike brings to this role 30 years of experience in manufacturing and operations with a strong focus in precision metal products, medical devices, continuous improvement, and strategic business planning," said Mark Augusti, President and Chief Executive officer. "I look forward to the contributions he will make as a member of the Conformis team." Michael Fillion Prior to joining Conformis, Michael served as the Executive Vice Pr

      4/1/22 5:00:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. Appoints Denise Pedulla as Chief Legal Officer and Corporate Secretary

      BILLERICA, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Denise Pedulla has joined the Company as its Chief Legal Officer and Corporate Secretary. "We are pleased to announce the addition of Denise Pedulla as Chief Legal Officer and Corporate Secretary. Her strong public company experience and leadership capabilities will help support our growth strategy and further strengthens our executive team," said Mark Augusti, President and Chief Executive Officer. "I look forward to the contributions she will make as a member of the Conformis team." Denise Pedulla Prior to joining Conformis, Denise served as the General Counsel and Corporate Secreta

      3/14/22 4:30:00 PM ET
      $CFMS
      Industrial Specialties
      Health Care
    • Conformis, Inc. Appoints James Paiva as its new Vice President of U.S. Marketing; Inducement Grant Reported

      BILLERICA, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed James Paiva as its new Vice President, U.S. Marketing. "Conformis is pleased to welcome James Paiva as the new V.P. of U.S. Marketing. As we continue to advance our growth strategy, we are confident that James' extensive background in new product introductions and multi-channel marketing will help to strengthen Conformis brand recognition and position us to capitalize on anticipated growth in the ambulatory surgery center space," said Mark Augusti, President and Chief Executive Officer.  "I look forward to the contributions James will make as a member of Confo

      11/8/21 9:00:00 AM ET
      $CFMS
      Industrial Specialties
      Health Care